title: Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course.
abstract: BACKGROUND
  Pregabalin (PGB) has been shown to improve sleep quality and health-related quality of life (HRQoL) as well as pain intensity in patients with neuropathic pain.
  
  
  OBJECTIVE
  The objective of the study was to explore the magnitude of the correlations between changes in pain intensity, sleep quality, and HRQoL after PGB treatment.
  
  
  METHODS
  One hundred thirty-eight patients with neuropathic pain of any origin and without an adequate response to analgesics received an 8-week treatment course of PGB in an open-label fashion. Pain intensity, sleep quality, and HRQoL outcomes were evaluated at baseline and at week 8 by means of an 11-point (0-10) numerical rating scale (NRS), the Pittsburgh Sleep Quality Index (PSQI), and the EuroQol health-state visuoanalogic scale (EQ-5D VAS) score, respectively.
  
  
  RESULTS
  At week 8, mean PGB dose was 166.7 ± 7.8 mg/d. Pain intensity NRS score, PSQI total score, and EQ-5D VAS score were improved by 66.5% ± 1.9%, 40.0% ± 3.6%, and 26.4% ± 4.7% (all P < 0.01), respectively. Correlations between percent change from baseline in pain NRS score and PSQI total score or EQ-5D VAS scores were r = 0.36 (P < 0.01, R = 0.11) and r = -0.20 (P < 0.02, R = 0.05), respectively. A multivariate logistic regression analysis disclosed that PSQI score change below the median (ie, a better outcome) was related to higher EQ-5D VAS score change (odds ratio, 2.15; 95% confidence interval, 1.09-4.25), whereas pain intensity NRS score change below the median was not (odds ratio, 1.58; 95% confidence interval,0.78-3.23).
  
  
  CONCLUSIONS
  In our study, PGB-related improvements in sleep quality and HRQoL were marginally related to reductions in pain intensity in patients with neuropathic pain. Improvement in sleep quality was a significant predictor of better HRQoL, whereas pain intensity reduction was not.
authors.affiliation: Pharmacology Department, Paul Sabatier University, Toulouse, France. splloret@fleni.org.ar
authors.forename: Santiago
authors.initials: S
authors.lastname: Perez-Lloret
authors.forename: Gloria Meza
authors.initials: GM
authors.lastname: Rojas
authors.forename: Maria Celia
authors.initials: MC
authors.lastname: Menoni
authors.forename: Gabriela
authors.initials: G
authors.lastname: Ruiz
authors.forename: Carolina
authors.initials: C
authors.lastname: Velásquez
authors.forename: Hernán
authors.initials: H
authors.lastname: Rodriguez
authors.forename: María Verónica
authors.initials: MV
authors.lastname: Rey
authors.forename: And Daniel P
authors.initials: AD
authors.lastname: Cardinali
mesh_terms: D000700:Analgesics / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000150:complications / Q000188:drug therapy* / Q000523:psychology*; D010147:Pain Measurement; D000069583:Pregabalin; D011788:Quality of Life / Q000523:psychology*; D012893:Sleep Wake Disorders / Q000188:drug therapy* / Q000209:etiology; D013223:Statistics as Topic; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid